Previous 10 | Next 10 |
2023-10-19 17:11:44 ET Gainers: PacWest Bancorp ( PACW ) +7% . Biomea Fusion ( BMEA ) +5% . Bank OZK ( OZK ) +3% . ADMA Biologics ( ADMA ) +3% . Revance Therapeutics ( RVNC ) +3% . Losers: SolarEdge Technologies ( SEDG ...
2023-09-11 17:20:07 ET Gainers: Matrix Service ( MTRX ) +10% . Adeia ( ADEA ) +7% . Allakos ( ALLK ) +5% . Nurix Therapeutics ( NRIX ) +5% . ADMA Biologics ( ADMA ) +4% . Losers: ACELYRIN ( SLRN ) ...
2023-08-10 14:31:53 ET Shares of ADMA Biologics (NASDAQ: ADMA) were up more than 12% as of 2 p.m. ET on Thursday. The healthcare company reported second-quarter earnings on Wednesday, after the markets closed. The stock is up more than 17% this year and reached a 52-week high on...
2023-08-09 20:52:03 ET ADMA Biologics, Inc. (ADMA) Q2 2023 Earnings Conference Call August 09, 2023, 16:30 ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director ...
2023-08-09 16:20:32 ET ADMA Biologics press release ( NASDAQ: ADMA ): Q2 GAAP EPS of -$0.03 in-line. Revenue of $60.13M (+77.4% Y/Y) beats by $4.63M . FY2024 and 2025 Total Revenue Guidance Increased to $275 Million vs $226.03M consensus and $325 Million or Mo...
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Ex...
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologi...
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and DALLAS, Ga., July 19, 2023 (GLOBE NEWSWIRE) -- AD...
2023-06-15 22:10:33 ET Summary ADMA continues its demonstrated sales performance with another tremendous growth in revenue for Q1 last month. There are fundamental, sentimental and valuation facts to suggest ADMA is mispriced in my opinion. Reiterate buy, seeking a 20% return ...
2023-05-10 21:02:04 ET ADMA Biologics, Inc. (ADMA) Q1 2023 Results Conference Call May 10, 2023 04:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Bria...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...